Solmi, Marco http://orcid.org/0000-0003-4877-7233
Croatto, Giovanni http://orcid.org/0000-0003-0591-3936
Piva, Giada
Rosson, Stella http://orcid.org/0000-0002-8554-3519
Fusar-Poli, Paolo http://orcid.org/0000-0003-3582-6788
Rubio, Jose M. http://orcid.org/0000-0002-0056-4135
Carvalho, Andre F. http://orcid.org/0000-0002-2500-5671
Vieta, Eduard http://orcid.org/0000-0002-0548-0053
Arango, Celso http://orcid.org/0000-0003-3382-4754
DeTore, Nicole R.
Eberlin, Elizabeth S.
Mueser, Kim T.
Correll, Christoph U.
Article History
Received: 27 May 2022
Revised: 21 July 2022
Accepted: 26 July 2022
First Online: 23 August 2022
Competing interests
: GC, SR, GP, NDT, EE, KTM have nothing to disclose. MS has been a consultant and/or advisor to or have received honoraria from Angelini, Lundbeck, Otsuka. EV has received grants and served as consultant, advisor or CME speaker for the following entities: Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Janssen, Lundbeck, Novartis, Otsuka, Raffo, Richter, Sage, Sanofi-Aventis, and Takeda, unrelated to the present work. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. PFP has received advisory consultancy fees from Lundbeck outside of this work. RS has received research support from Roche, Janssen, GSK and Takeda outside of this work. CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma.